共 50 条
Pulmonary Hypertension How to Best Treat the Different Scleroderma Phenotypes?
被引:1
作者:
Korman, Benjamin D.
[1
]
Lachant, Daniel J.
[2
]
Castelino, Flavia, V
[3
]
机构:
[1] Univ Rochester, Div Allergy Immunol & Rheumatol, Med Ctr, 601 Elmwood Ave,Box 695, Rochester, NY 14642 USA
[2] Univ Rochester, Div Pulm & Crit Care Med, Med Ctr, 601 Elmwood Ave,Box 692, Rochester, NY 14642 USA
[3] Massachusetts Gen Hosp, Div Rheumatol, 55 Fruit St,Yawkey 4B, Boston, MA 02114 USA
关键词:
Scleroderma;
Systemic sclerosis;
Pulmonary hypertension;
Screening;
Treatment;
RIGHT-HEART CATHETERIZATION;
SYSTEMIC-SCLEROSIS PATIENTS;
BASE-LINE CHARACTERISTICS;
ARTERIAL-HYPERTENSION;
IMMUNOSUPPRESSIVE THERAPY;
FERRIC CARBOXYMALTOSE;
COMBINATION THERAPY;
DISEASE;
DIAGNOSIS;
AMBRISENTAN;
D O I:
10.1016/j.rdc.2023.01.015
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Pulmonary hypertension in SSc is a multifactorial illness, which can have features of any of the WHO PH classes and often results from more than one pathophysiology. Advances in diagnosis and screening have allowed for earlier detection and treatment of less severe disease, which should improve outcomes. Treatment modalities are evolving and most patients will require a combination of therapies and care from an interdisciplinary team of specialists in rheumatology, pulmonology, and cardiology. A better understanding of disease mechanisms has led to novel diagnostic and treatment strategies to specifically address each patient's PH phenotype and improve outcomes in this challenging disease.
引用
收藏
页码:345 / 357
页数:13
相关论文
共 50 条